August 24, 2015
Eli Lilly Japan said on August 21 that it has filed a new drug application in Japan for its humanized anti-interleukin-17A monoclonal antibody ixekizumab (recombinant) for the treatment of moderate to severe psoriasis vulgaris, pustular psoriasis, erythrodermic psoriasis and psoriasis...read more